Header menu link for other important links
X
Global metabolic consequences of the chromogranin A-null model of hypertension: Transcriptomic detection, pathway identification, and experimental verification
Published in
2010
PMID: 19952279
Volume: 40
   
Issue: 3
Pages: 195 - 207
Abstract
Chromogranin A (CHGA) has a crucial role in formation of regulated secretory granules in neuroendocrine tissues and is also a prohormone that is proteolytically processed into peptides with diverse and complex actions. CHGA and several of its peptide products, including catestatin and pancreastatin, are implicated in pathogenesis of essential hypertension, insulin resistance, and the metabolic syndrome. The Chga knockout mouse (Chga KO) displays severe hypertension coupled with reduction in size, number, and density of regulated secretory granules. We performed genome-wide transcriptome profiling in Chga KO adrenal gland and liver for insight into biochemical and physiological systems altered in this monogenic mouse model of hypertension. Adrenal gene expression pathway prediction of enhanced insulin sensitivity (P = 0.03) in Chga KO was confirmed with glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) measurements: blood glucose was normal in Chga KO, blood insulin was reduced 4.5-fold (P < 0.0001), and HOMA-IR was decreased 3.8-fold (P < 0.002). Remarkably, such observations conclusively dissociate fundamental features of the metabolic syndrome in this monogenic hypertension model. Exogenous pancreastatin treatment restored insulin sensitivity in the Chga KO to near-normal levels. Gene expression predictions of decreased adrenal cholesterol biosynthesis (P < 0.001) and increased hepatic cholesterol biosynthesis (P < 0.001) were verified with tissue total cholesterol assays: Chga KO adrenal cholesterol decreased 1.8-fold (P = 0.039) and hepatic cholesterol increased 1.8-fold (P = 0.018). Transcriptional regulatory network prediction identified sets of transcription factors that may provide insight into the unclear mechanistic links among CHGA, cholesterol, insulin sensitivity, and the metabolic syndrome. These experiments demonstrate, for the first time, that genetic variation at the CHGA locus impacts insulin sensitivity and tissue cholesterol levels in an intact, living organism. The Chga KO may constitute a unique model for studying the relationship between the CHGA locus and disease phenotypes of the metabolic syndrome.
About the journal
JournalPhysiological Genomics
ISSN10948341
Open AccessNo
Concepts (38)
  •  related image
    Cholesterol
  •  related image
    Chromogranin a
  •  related image
    Glucose
  •  related image
    Insulin
  •  related image
    Pancreastatin
  •  related image
    Transcriptome
  •  related image
    Triacylglycerol
  •  related image
    ADRENAL GLAND
  •  related image
    Animal experiment
  •  related image
    Animal model
  •  related image
    Article
  •  related image
    Cholesterol synthesis
  •  related image
    Controlled study
  •  related image
    ESSENTIAL HYPERTENSION
  •  related image
    Gene expression
  •  related image
    Genetic variability
  •  related image
    Glucose blood level
  •  related image
    INSULIN BLOOD LEVEL
  •  related image
    Insulin resistance
  •  related image
    INSULIN SENSITIVITY
  •  related image
    KNOCKOUT MOUSE
  •  related image
    Liver
  •  related image
    Metabolic syndrome x
  •  related image
    Microarray analysis
  •  related image
    Mouse
  •  related image
    Nonhuman
  •  related image
    Priority journal
  •  related image
    Secretory granule
  •  related image
    Transcription regulation
  •  related image
    Wild type
  •  related image
    Animals
  •  related image
    Blood glucose
  •  related image
    Gene expression profiling
  •  related image
    Hypertension
  •  related image
    Mice
  •  related image
    MICE, KNOCKOUT
  •  related image
    MICE, TRANSGENIC
  •  related image
    Models, animal